KNTPF (Kintor Pharmaceutical) Buildings And Improvements : $14.95 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Buildings And Improvements?

Kintor Pharmaceutical's quarterly buildings and improvements declined from Dec. 2023 ($15.42 Mil) to Jun. 2024 ($0.00 Mil) but then increased from Jun. 2024 ($0.00 Mil) to Dec. 2024 ($14.95 Mil).

Kintor Pharmaceutical's annual buildings and improvements declined from Dec. 2022 ($15.59 Mil) to Dec. 2023 ($15.42 Mil) and declined from Dec. 2023 ($15.42 Mil) to Dec. 2024 ($14.95 Mil).

Kintor Pharmaceutical Buildings And Improvements Historical Data

The historical data trend for Kintor Pharmaceutical's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Buildings And Improvements Chart

Kintor Pharmaceutical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buildings And Improvements

Get a 7-Day Free Trial

9.92

10.66

15.59

15.42

14.95

Kintor Pharmaceutical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Buildings And Improvements	Get a 7-Day Free Trial								15.59	-	15.42	-	14.95

Kintor Pharmaceutical Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Kintor Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (OTCPK:KNTPF) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

09939:Hong Kong

Address

No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.kintor.com.cn

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.